Roy is Senior Vice President of Biology at C4 Therapeutics. Prior to joining C4 Therapeutics, Dr. Pollock was Vice President of Biology at Warp Drive Bio (acquired by Revolution Medicines) where he guided the discovery and characterization of inhibitors targeting the activated form of mutant KRAS using a novel tri-complex technology platform. Prior to joining Warp Drive, Dr. Pollock was at Epizyme where he led biology support for histone methyltransferase inhibitors targeting DOT1L (Pinometostat) and EZH2 (Tazverik™). Prior to Epizyme, Dr Pollock worked in oncology drug discovery at Merck Research Laboratories and ARIAD Pharmaceuticals. He holds a B.Sc. in biochemistry from St Andrews University in Scotland and a Ph.D. in Molecular Biology from Imperial College London.